A clinical study of Dan Hong injection mobilizing peripheral blood endothelial progenitor cells to repair endothelial injury in patients with coronary heart disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004100

Enrollment

Unknown

Registered

2014-01-02

Start date

2014-01-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

SA-control group:Conventional western medicine treatment

SA-experimental group:Conventional western medicine treatment combined with Dan Hong injection

UA-control group:Conventional western medicine treatment

UA-experimental group:Conventional western medicine treatment combined with Dan Hong injection

CHD treated with PCI-control group:Conventional western medicine treatment

CHD treated with PCI-experimental group:Conventional western medicine treatment combined with Dan Hong injection

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The subjects meet the diagnostic criteria of coronary heart disease (including SA, UA patients treated with drug and SA, ACS patients treated with PCI), who have angina symptoms and/or the objective evidence of myocardial ischemia; 2. The subjects aged 35-75 years old; 3. The subjects whose clinical observational data is completed; 4. The subjects agreed to test related indicators.

Exclusion criteria

Exclusion criteria: 1. People who do not conform to the diagnostic criteria of western medicine; 2. People who do not conform to the age requirement; 3. .People with Serious primary disease of the liver, kidney, hematopoietic system and other vital organs; 4. patients with clear infection, tumor; patients with connective tissue disease, autoimmune disease; people who underwent recent surgery, or trauma; 5. Pregnancy, lactating women, mental disorder; 6. Patients with peripheral vascular disease, cerebrovascular disease; 7. patients with CHD who received revascularization treatment again; 8. People who are allergy or intolerant to the experimental drug; 9. People who participated in any other clinical trials within 3 months; 10. Any medical history which may interfere with the test results or increase the risk of patients judged by the researchers; 11. The subjects refused to test related indicators.

Design outcomes

Primary

Measure	Time frame
the number and the function of EPCs;the number of CECs;1H-NMR metabolic fingerprints of plasma and urine;protein binding rate;level of inflammatory factors(TNF-alpha, hs-CRP, vWF, IL-6, MCP-1);	—

Countries

China

Contacts

Public ContactGao XiuMei

Tianjin University of Traditional Chinese Medicine (TCM)

gaoxiumei@tjutcm.edu.cn+86 13602020716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026